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ABSTRACT: The ﬁrst general two-step, one-pot synthetic
route to 6-azopurines is presented. Microwave-assisted
nucleophilic aromatic substitution of protected 6-chloropurines
with hydrazines or hydrazides, followed by metal-free oxidation
with oxygen, gives 6-azopurines in high to excellent yields.
Photophysical studies revealed intensive n−π* absorption band
that makes trans-to-cis photoswitching possible using visible
light (λ = 530 nm).
Controlling biological processes with light is an emergingﬁeld of chemical biology.1 It oﬀers high spatiotemporal
resolution and bioorthogonality, and it generates no waste.
Biological functions can be controlled with light using
molecular photoswitches on the oligonucleotide,1a,d,e,2 small
molecule,3 or genetic level.1a,d,e,2a,4 Photopharmacology repre-
sents the recently introduced concept of reversible photo-
control over the activity of small molecules. This type of
regulation relies on the incorporation of a photoswitchable
moiety into bioactive molecule to achieve a very precise control
through on- and oﬀ-switching of their activity by light.3c−e
Similarly, photomanipulation of genetic processes can be
achieved through reversible modulation of structure and
function of DNA and RNA by incorporating a molecular
photoswitch into structures of oligonucleotides.5 Translation
and transcription are essential processes in the cell, and their
photoregulation could therefore provide insight into many
biological mechanisms. Through these applications, in the past
decade both photopharmacology and the application of
reversibly photocontrolled oligonucleotides provided important
alternatives to optogenetics,4 which uses genetic manipulation
to introduce photoresponsive ion channels to cells.
Nucleobases, as parts of nucleotides and nucleosides, are
fundamental building blocks of DNA and RNA, as well as other
biologically important molecules. For example, ATP and GTP
are involved in many crucial cell activities, such as energy
storage and signal transduction pathways.6 Furthermore,
structures of many kinase inhibitors and other biologically
relevant molecules are based on a purine scaﬀold (Figure 1,
compounds A1−A5).7 Despite some side eﬀects (nausea,
vomiting, hyperglycemia, etc.), some of these compounds have
already reached clinical phase research, illustrating the
importance of purine moieties in drug discovery.8 In order to
reduce side eﬀects of purine-based drugs, one of the biggest
challenges is precise spatiotemporal control of their activity in
biological processes involving DNA, RNA, and kinases.
Toward this goal, a photochromic unit needs to be
introduced into the structure of a nucleobase to render it
photoresponsive and thereby controllable by light. This must
be achieved without compromising the activity and function of
these molecules, which implies that the structural perturbation
caused by the incorporation of the photochromic unit has to be
as subtle as possible. Moreover, concerning the application of
these photoresponsive molecules in biological systems, an
additional and major challenge is to ensure control by visible
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Figure 1. (A) Bioactive molecules with a purine scaﬀold; (B) examples
of photoswitchable nucleotides; (C) structures enabled by this work.
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light. For these purposes, azobenzenes are undoubtedly the
most suitable and widely used organic chromophores, due to
their photostability, high tunability, and low molecular
weight.1a,b,4,9
Examples of successful transformation of the purine scaﬀold
into a photoswitchable unit are, however, scarce and mainly
focused on positions 2 and 8 of the structure (for example B1
and B2; Figure 1B).5 To the best of our knowledge, position 6
has never been directly modiﬁed into a heterocyclic
azobenzene, even though it appears to be the most promising
position for incorporation of a photoswitch that allows to
preserve the original molecular function (see examples A1−A5
in Figure 1).10
Constructing a heterocyclic azobenzene at the position 6
would impose a minor structural change in adenine and
guanine while preserving a nitrogen atom that acts as a good
hydrogen-bond acceptor. This, however, poses a synthetic
challenge due to the low nucleophilicity of the 6-amino group
of purines. The only existing example in the literature, which
also highlights the diﬃculty to directly modify the 6-amino
group, is the indirect attachment of the whole azobenzene
scaﬀold through amide bond formation.11
With this in mind, we were interested in the development of
a general synthetic approach for the incorporation of an
azobenzene moiety to the pyrimidine ring of purines (Figure
1C). Our initial attempts to make 6-azopurines by commonly
employed synthetic methods for azobenzenes, such as Mills
reaction5c,12 and diazo coupling,13 were not successful in
functionalizing the unreactive 6-amino group. We further
attempted to apply Pd-catalyzed coupling reaction of aryl
hydrazides with 6-chloro-9-isopropyladenine (compound 1,
Figure 2), followed by NBS oxidation in pyridine.14 However,
none of the reaction conditions that were screened aﬀorded the
desired coupling product (for details, see Scheme S1).
Finally, we focused on the easily accessible N-Boc-hydrazide
2 (Figure 2),15 that we subjected to a simple, uncatalyzed
nucleophilic aromatic substitution with 6-chloro-9-isopropyla-
denine 1, aiming to synthesize N-Boc-N,N′-diaryl hydrazide 3
that could be further deprotected and oxidized to the desired
azo compound. However, under the reaction conditions
(equimolar 1 and 2, n-BuOH as a solvent, DIPEA as a base,
rt to 60 °C), no product formation was observed and the
starting material was quantitatively recovered. Then a reaction
was submitted to microwave irradiation at 150 °C for 2 h,
followed by 12 h of storage at room temperature. A red-brown
layer was observed on the top of a yellow solution. NMR and
MS analysis of precisely taken aliquots showed that the upper
layer was consisted of pure heterocyclic azobenzene 6, whereas
the yellow layer gave a pure spectrum of N,N′-diarylhydrazine 4
(Figure 2; see Figure S1).
From this unexpected observation, we hypothesized (Figure
2) that hydrazine 4 was formed either by deprotection of
compound 3 (route A) or by deprotection of 2, followed by
nucleophilic aromatic substitution with 5 (route B). Compound
2 was thus submitted to the same reaction conditions (without
substrate 1 present), and the TLC analysis showed slow in situ
conversion of N-Boc-3-methylphenyl hydrazide 2 to hydrazine
5. This led us to the conclusion that the synthesis of such
heterocyclic azo-compounds can be performed both by using
commercially available arylhydrazines and N-Boc-aryl hydra-
zides. Indeed, in reaction with compound 1, hydrazine 5 gave
the same yield (93%) of compound 4 as starting from
compound 2.
The second remarkable observation was the in situ formation
of 6-azoadenine 6. The only available oxidant for this reaction
was oxygen from the limited volume of air in the vessel. Slow
diﬀusion of air through the solution could explain formation of
the colored layer on the top of the reaction mixture (see Figure
S1a). Therefore, two aliquots of the same microwave irradiated
reaction were submitted to the diﬀerent sources of oxygen−air
and balloon ﬁlled with pure oxygen. After few minutes, it was
already clear by color change that reaction under oxygen
atmosphere proceeds much faster, and after only 2 h it gave
pure oxidation product 6 in 93% yield. Reaction conducted
under the air did not reach full conversion even after 16 h of
vigorous stirring (Figure S1b). This result is highly promising
since oxidation of diaryl hydrazines does not require use of
transition metals,16 and it is fully compatible with initial
reaction conditions of nucleophilic aromatic substitution. The
signiﬁcance of the newly introduced reaction sequence lies in
the successful synthesis of important heterocyclic azobenzenes
in a one-pot, two-step procedure, merging two consecutive
reactions.
Further optimization of reaction conditions included a
screening of the temperature (25, 60, and 150−180 °C with
MW irradiation), base (K2CO3, Cs2CO3, K3PO4, and DIPEA)
and solvent (DMSO, n-BuOH, CH3CN, and THF). We found
that the reaction at 150 °C (for adenines) or 180 °C (for
guanines) in n-BuOH showed the fastest rate for nucleophilic
aromatic substitution in the presence of DIPEA as a base.
A library of 18 6-azoadenines and eight 6-azoguanines was
prepared to study the substrate scope (Scheme 1) by using
both electron-rich and electron-poor hydrazines while main-
taining 6-chloro-9-isopropyladenine (1) and 6-chloro-9-iso-
propylguanine (8) scaﬀolds for nucleophilic aromatic sub-
stitution. The use of an N-isopropyl substituent on 6-
chloropurines eﬀectively mimicked the secondary carbon
atom that is commonly attached to purines in nucleotides at
position 9. Under the optimized conditions, all products were
obtained in high to excellent yields using unprotected
substrates in a simple experimental procedure (Scheme 1; see
the SI).
Nucleophilic aromatic substitution on substrate 1 was
successfully performed upon MW heating at 150 °C in n-
BuOH in the presence of DIPEA as base, while the reaction
temperature for substitution on compound 8 had to be
increased to 180 °C. This can be explained by the presence of
an additional 2-amino group that decreases the electrophilicity
of the guanine core, which aﬀects the reaction time of
nucleophilic aromatic substitution. The reaction time increased
Figure 2. Representation of the two proposed pathways for the
synthesis of azobenzene 6, which either involve a three-step approach
(route A) or a two-step, one-pot synthesis (route B).
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from 1 to 2 h, when substrate 1 was used, to 3 h in the case of 8
(Scheme 1). Moreover, it was found that the nature of the
substituents on phenyl hydrazine precursors plays an important
role regarding the reaction time of nucleophilic aromatic
substitution. We have observed a slight increase of reaction
time when hydrazines bearing electron-withdrawing substitu-
ents were employed. The reaction time of the oxidation also
increased signiﬁcantly in case of electron-poor diaryl hydrazines
(from 1 h for 6b to 24 h for 6r; Scheme 1). On the other hand,
the minute amounts of side products in the reaction with
electron-poor hydrazines decreased, allowing pure products to
be obtained after simple column chromatography. Otherwise,
recrystallization from ethyl acetate/pentane was used to obtain
pure target compounds.
This hydrazine substituent eﬀect was further assessed by
analyzing a series of hydrazines (7a−r) in the reaction with 1
(Scheme 1). At the speciﬁed reaction times, no obvious steric
and electronic eﬀects on the reaction yields were observed with
a variety of meta- and para-substituted hydrazines (6a−m, 9a−
g). To our satisfaction, optimized conditions also tolerated
diﬀerent ortho-substituents (F, Cl, Me), despite the reported
challenges in the synthesis of recently developed highly desired
ortho-substituted azobenzenes,17 yielding products in high
yields (6n, 6o, and 6r). Nucleophilic substitution with sterically
demanding 2-naphthyl hydrazine, an extended aromatic system,
also worked (6p, 9h). Furthermore, the reaction was eﬃcient
even for highly electron-deﬁcient substrates, such as 2,4,6-
triﬂorophenylhydrazine, whereas the only tested hydrazine that
did not provide the desired product was pentaﬂuorophenylhy-
drazine.
The photophysical properties of the synthesized 6-azopurines
were explored for representative cases of both adenine (6o)
and guanine (9f) analogues. We examined a few characteristic
parameters, including UV−vis absorption maxima (λmax),
photoswitchability, photostationary state (PSS), and fatigue
resistance upon long-term irradiation (for details, see the SI).
First, biological applications require red-shifted photo-
switches that absorb in the visible spectral region, which
enables lower energy inputs, deeper penetration, and lower
toxicity.17,18 UV−vis absorption spectroscopy revealed that all
of the representative examples of azopurines absorb in the
visible spectral domain with absorption maxima (λmax) that are
summarized in Figure 3. UV−vis spectra featured two
characteristic signals, one of which can be assigned to a
π−π* transition, whereas the other lower energy band from the
n−π* transitions.
The absorption that corresponds to the n−π* transitions was
found to be weak for azoadenines, whereas it presented a strong
contribution for azoguanines reﬂected in their higher extinction
coeﬃcients. Furthermore, substituent eﬀects on the spectral
features were apparent. In this regard, electron-donating groups
were found to induce a bathochromic shift of the π−π*
transition, whereas para-substituted azopurines showed partic-
ularly good correlation between λmax and σpara Hammett
parameter (for details, see Figure S50). This implies that
para-substitution could act as an important design principle for
azopurines, enabling red-shifted π−π* transition. Moreover, an
interesting trend has been observed in red-shifting of n-π*
transitions. Additional amino groups in guanines increase the
electronic density and clearly lead to a hypsochromic shift
(compounds 9a−g, Figure 3). Remarkably, despite the
literature expectations on the ortho eﬀect,17 substitution with
carboxylic group in the meta position yielded the most
bathochromically shifted 6-azopurine (6k). This surprising
outcome is probably related to the presence of an acidic group
that can protonate the purine core making it even more
electron withdrawing.
Next, the photoswitchability of representative azopurines was
investigated, and we found that green light (λ = 530 nm) can be
used for trans-to-cis photoisomerization of both adenine and
guanine analogues. This photoexcitation relied on promoting
the low energy n-π* transition, which was eﬀective for both
adenine and guanine analogs. The photoswitchability was
assessed for compounds 6o and 9f upon irradiation at 530 nm
that resulted in a PSS characterized by trans/cis isomer ratios of
58:42 for 6o and 36:64 for 9f, as determined by 1H NMR
spectroscopy (for details, see Figures S36−38). This ﬁnding
thereby further supported the relevance of these systems in
biological applications.
Finally, an important prerequisite for application of photo-
switches is low switching fatigue. Remarkably, even after
Scheme 1. Synthetic Sequence for Obtaining Diverse 6-
Azopurinesa
aReaction conditions: (1) 1 or 8 (0.36 mmol), 7 (1.2 equiv), DIPEA
(5 equiv), n-BuOH (2 mL), 150 or 180 °C, 1−3 h; (2) O2, rt.
bIsolated yield after column chromatography. c2.8 mmol scale. Figure 3. Spectral map that summarizes the absorption maxima (λmax)
that correspond to a low energy n−π* transition for a series of 6-
azopurines based on adenine (6a−r) and guanine (9a−h) scaﬀolds
(structures are summarized in Scheme 1).
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exposure to UV light at 365 nm (photon ﬂux, Φ = 1.46 × 10−9
mol s−1) over a period of 12 h, the representative examples,
such as 6a, showed very little fatigue (below 25% over >50
cycles) as exempliﬁed by multiple cycles of switching in PBS
buﬀer at physiological pH (see Figures S33−34). This analysis
highlights desirable photophysical properties of a new
generation of azopurines that make them promising candidates
for further applications in biological systems.
In summary, we demonstrate an eﬃcient and versatile
synthetic route to a range of new heterocyclic azobenzenes
based on the purine scaﬀold. A series of 6-azopurines from
commercially available arylhydrazines and 6-chloro-9-isopropy-
ladenine 1 or 6-chloro-9-isopropylguanine 8 were obtained in
high yield. The generality of this method has been
demonstrated through the nucleophilic aromatic substitution
followed by oxidation of a wide variety of substitutedboth
electron-rich and electron-poorphenylhydrazines. Final com-
pounds are shown to have red-shifted absorption maxima
featuring high fatigue resistance. Their synthetic accessibility,
high stability, and visible-light-mediated isomerization make
them ideal for biological applications. Further investigation of
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